MaxCyte, Inc. Increase (Decrease) in Other Current Assets
MaxCyte, Inc. (MXCT) reported Increase (Decrease) in Other Current Assets of -$1.12 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2022-05-09
- MaxCyte, Inc. increase (decrease) in other current assets for the quarter ending 2022-03-31 was -$1.12M.
- MaxCyte, Inc. increase (decrease) in other current assets for the quarter ending 2021-12-31 was -$234.50K.
- MaxCyte, Inc. increase (decrease) in other current assets for the quarter ending 2021-09-30 was $2.20M, a 498.91% increase year-over-year.
- MaxCyte, Inc. increase (decrease) in other current assets for the quarter ending 2021-06-30 was $360.40K.
- MaxCyte, Inc. increase (decrease) in other current assets for fiscal 2021 was $2.30M, a 1019.18% increase from fiscal 2020.
- MaxCyte, Inc. increase (decrease) in other current assets for fiscal 2020 was $205.90K.
- MaxCyte, Inc. increase (decrease) in other current assets for fiscal 2019 was -$66.60K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$1.12M 10-Q · filed 2022-05-09 | -$1.35M derived: sum of 2 quarters · filed 2022-05-09 | $844.50K derived: sum of 3 quarters · filed 2022-05-09 | $1.20M derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | -$234.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $1.96M derived: sum of 2 quarters · filed 2022-03-22 | $2.32M derived: sum of 3 quarters · filed 2022-03-22 | $2.30M 10-K · filed 2022-03-22 |
| 2021-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.56M derived: sum of 2 quarters · filed 2021-11-10 | $2.54M 10-Q · filed 2021-11-10 | $2.39M derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-06-30 | $360.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-09-13 | $342.70K 10-Q · filed 2021-09-13 | $191.60K derived: sum of 3 quarters · filed 2022-05-09 | $558.30K derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-03-31 | -$17.70K 10-Q · filed 2022-05-09 | -$168.80K derived: sum of 2 quarters · filed 2022-05-09 | $197.90K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | -$151.10K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $215.60K derived: sum of 2 quarters · filed 2022-03-22 | $205.90K 10-K · filed 2022-03-22 | |
| 2020-09-30 | $366.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $357.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$9.70K 10-Q · filed 2021-09-13 | |||
| 2019-12-31 | -$66.60K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |